Shandong Buchang Pharmaceuticals Co., Ltd. Stock

Equities

603858

CNE100002FV6

Pharmaceuticals

End-of-day quote Shanghai S.E. 18:00:00 2024-07-17 EDT 5-day change 1st Jan Change
15.17 CNY +0.60% Intraday chart for Shandong Buchang Pharmaceuticals Co., Ltd. -0.98% -10.82%

Financials

Sales 2022 14.95B 2.06B 2.82B Sales 2023 13.25B 1.82B 2.5B Capitalization 18.81B 2.59B 3.55B
Net income 2022 -1.66B -228M -313M Net income 2023 319M 43.89M 60.18M EV / Sales 2022 1.58 x
Net Debt 2022 422M 58.03M 79.58M Net Debt 2023 2.25B 309M 424M EV / Sales 2023 1.59 x
P/E ratio 2022
-14 x
P/E ratio 2023
59 x
Employees 8,311
Yield 2022
4.57%
Yield 2023
0.74%
Free-Float 41.28%
More Fundamentals * Estimated data
Dynamic Chart
Shandong Buchang Pharmaceuticals Co., Ltd. announces an Increase in Equity Buyback. CI
Shandong Buchang Pharmaceuticals Gets China Nod for Cholesterol Control Tablets MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 14, 2023. CI
Buchang Pharma Obtains Green Light to Trial Gastric Cancer Drug Combination MT
Tranche Update on Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 14, 2023. CI
Buchang Pharma’s Drugs Retain National Medical Insurance Coverage MT
Shandong Buchang Pharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 360 million worth of its shares. CI
Shandong Buchang Pharmaceuticals Co., Ltd. authorizes a Buyback Plan. CI
Buchang Pharma's Unit Gets Nod to Test Colorectal Cancer Drug MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Haikou Xinyingyang Investment Partnership Enterprise (Limited Partnership) and Xi Chong agreed to acquire 14% stake in Buchang Health Industry (Zhejiang ) Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd.,Hu Cunchao, Li Hui, and Hu Cunchao for CNY 0. CI
Buchang Pharma Unit Gets Nod to Trial Cancer Treatment MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
More news
1 day+0.60%
1 week-0.98%
Current month+0.13%
1 month-1.11%
3 months-9.70%
6 months-4.83%
Current year-10.82%
More quotes
1 week
14.87
Extreme 14.87
15.50
1 month
14.40
Extreme 14.4
15.64
Current year
14.15
Extreme 14.15
18.13
1 year
14.15
Extreme 14.15
20.73
3 years
14.15
Extreme 14.15
28.38
5 years
14.15
Extreme 14.15
33.12
10 years
14.15
Extreme 14.15
91.96
More quotes
Managers TitleAgeSince
Director of Finance/CFO 60 12-03-10
President 57 12-03-10
Chief Tech/Sci/R&D Officer 65 17-03-25
Members of the board TitleAgeSince
Chairman 58 12-03-10
Director/Board Member 50 12-03-10
Director/Board Member 57 01-05-09
More insiders
Date Price Change Volume
24-07-18 15.17 +0.60% 2,888,640
24-07-17 15.08 +0.13% 3,130,942
24-07-16 15.06 -1.83% 2,931,144
24-07-15 15.34 -1.10% 2,522,459
24-07-12 15.51 +1.24% 4,668,682

End-of-day quote Shanghai S.E., July 17, 2024

More quotes
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Company’s main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603858 Stock